Missing Data in Longitudinal Clinical Trials Part A: Design and Conceptual Issues.
作者信息
Lavori Philip W, Brown C Hendricks, Duan Naihua, Gibbons Robert D, Greenhouse Joel
机构信息
Biostatistics and Department of Health Research and Policy, Stanford University School of Medicine.
出版信息
Psychiatr Ann. 2008 Dec 1;38(12):784-792. doi: 10.3928/00485713-20081201-04.
Abstract
摘要
相似文献
1
Missing Data in Longitudinal Clinical Trials Part A: Design and Conceptual Issues.
Psychiatr Ann. 2008 Dec 1;38(12):784-792. doi: 10.3928/00485713-20081201-04.
3
Review of guidelines and literature for handling missing data in longitudinal clinical trials with a case study.
Pharm Stat. 2006 Jan-Mar;5(1):7-18. doi: 10.1002/pst.189.
4
Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset.
Arch Gen Psychiatry. 1993 Sep;50(9):739-50. doi: 10.1001/archpsyc.1993.01820210073009.
5
Making an unknown unknown a known unknown: Missing data in longitudinal neuroimaging studies.
Dev Cogn Neurosci. 2018 Oct;33:83-98. doi: 10.1016/j.dcn.2017.10.001. Epub 2017 Oct 28.
6
Handling missing data issues in clinical trials for rheumatic diseases.
Contemp Clin Trials. 2011 Jan;32(1):1-9. doi: 10.1016/j.cct.2010.09.001. Epub 2010 Sep 16.
7
Missing Data in Longitudinal Trials - Part B, Analytic Issues.
Psychiatr Ann. 2008 Dec 1;38(12):793-801. doi: 10.3928/00485713-20081201-09.
8
On the joys of missing data.
J Pediatr Psychol. 2014 Mar;39(2):151-62. doi: 10.1093/jpepsy/jst048. Epub 2013 Jul 8.
9
Methodological Issues in Analyzing Real-World Longitudinal Occupational Health Data: A Useful Guide to Approaching the Topic.
Int J Environ Res Public Health. 2022 Jun 8;19(12):7023. doi: 10.3390/ijerph19127023.
10
Statistical analysis of randomized trials in tobacco treatment: longitudinal designs with dichotomous outcome.
Nicotine Tob Res. 2001 Aug;3(3):193-202. doi: 10.1080/14622200110050411.
引用本文的文献
1
Impulsivity profiles across five harmonized longitudinal childhood preventive interventions and associations with adult outcomes.
Dev Psychopathol. 2025 May;37(2):990-1003. doi: 10.1017/S0954579424000828. Epub 2024 Apr 24.
2
Assessing the performance of different outcomes for tumor growth studies with animal models.
Animal Model Exp Med. 2022 Sep;5(3):248-257. doi: 10.1002/ame2.12250. Epub 2022 Jun 14.
3
Methodological Considerations for Advancing Research on the Health and Wellbeing of Sexual and Gender Minority Youth.
LGBT Health. 2019 May-Jun;6(4):156-165. doi: 10.1089/lgbt.2018.0141.
4
Addressing Methodologic Challenges and Minimizing Threats to Validity in Synthesizing Findings from Individual-Level Data Across Longitudinal Randomized Trials.
Prev Sci. 2018 Feb;19(Suppl 1):60-73. doi: 10.1007/s11121-017-0769-1.
5
Measures of outcome for stimulant trials: ACTTION recommendations and research agenda.
Drug Alcohol Depend. 2016 Jan 1;158:1-7. doi: 10.1016/j.drugalcdep.2015.11.004. Epub 2015 Nov 21.
6
How to avoid missing data and the problems they pose: design considerations.
Shanghai Arch Psychiatry. 2012 Jun;24(3):181-4. doi: 10.3969/j.issn.1002-0829.2012.03.010.
7
Patient reported endpoints for measuring clinical benefit in (high grade glioma) primary brain tumor patients.
Curr Treat Options Oncol. 2014 Dec;15(4):519-28. doi: 10.1007/s11864-014-0302-8.
8
Toward empirical identification of a clinically meaningful indicator of treatment outcome: features of candidate indicators and evaluation of sensitivity to treatment effects and relationship to one year follow up cocaine use outcomes.
Drug Alcohol Depend. 2014 Apr 1;137:3-19. doi: 10.1016/j.drugalcdep.2014.01.012. Epub 2014 Jan 31.
9
The design and conduct of clinical trials to limit missing data.
Stat Med. 2012 Dec 10;31(28):3433-43. doi: 10.1002/sim.5519. Epub 2012 Jul 25.
10
Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine.
Arch Gen Psychiatry. 2012 Jun;69(6):572-9. doi: 10.1001/archgenpsychiatry.2011.2044.
本文引用的文献
1
Missing Data in Longitudinal Trials - Part B, Analytic Issues.
Psychiatr Ann. 2008 Dec 1;38(12):793-801. doi: 10.3928/00485713-20081201-09.
2
Methods for testing theory and evaluating impact in randomized field trials: intent-to-treat analyses for integrating the perspectives of person, place, and time.
Drug Alcohol Depend. 2008 Jun 1;95 Suppl 1(Suppl 1):S74-S104. doi: 10.1016/j.drugalcdep.2007.11.013. Epub 2008 Jan 22.
3
The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials.
Stat Med. 2007 Jan 15;26(1):20-36. doi: 10.1002/sim.2739.
4
Analyzing incomplete longitudinal clinical trial data.
Biostatistics. 2004 Jul;5(3):445-64. doi: 10.1093/biostatistics/5.3.445.
5
A case study on the choice, interpretation and checking of multilevel models for longitudinal binary outcomes.
Biostatistics. 2001 Dec;2(4):397-416. doi: 10.1093/biostatistics/2.4.397.
6
A mixed-effects multinomial logistic regression model.
Stat Med. 2003 May 15;22(9):1433-46. doi: 10.1002/sim.1522.
7
Beyond intention to treat.
Epidemiol Rev. 2002;24(1):85-90. doi: 10.1093/epirev/24.1.85.
8
Principal stratification in causal inference.
Biometrics. 2002 Mar;58(1):21-9. doi: 10.1111/j.0006-341x.2002.00021.x.
9
MIXOR: a computer program for mixed-effects ordinal regression analysis.
Comput Methods Programs Biomed. 1996 Mar;49(2):157-76. doi: 10.1016/0169-2607(96)01720-8.
10
Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset.
Arch Gen Psychiatry. 1993 Sep;50(9):739-50. doi: 10.1001/archpsyc.1993.01820210073009.
Zotero 插件